Publications by authors named "G J Bene"
This article investigates the effects of tobacco control policies on smoking initiation, cessation and prevalence by examining the papers published in the last 5 years. Twenty-one articles have been selected by two authors and sorted by four types of tobacco control: tobacco prices, anti-smoking campaigns for young people, mass media intervention and public smoking bans. Price/tax increase has deterrent effect on smoking initiation but does not promote smoking cessation; intervention on young people could reduce the smoking initiation if carried out at an early age and if acted on social skills and with peer-led approach, as opposed to restraining measures which hare generally easily circumvented by young people.
View Article and Find Full Text PDFSmoking is recognized as the major cause of lung cancer. Healthcare professionals play an important role in lung cancer prevention policies, as they act as a source of guidance for patients and advocates. The following survey evaluated prevalence, knowledge, and attitudes toward tobacco smoking among a sample of workers in "IRCCS Istituto Tumori "Giovanni Paolo II" of Bari, an Italian cancer hospital.
View Article and Find Full Text PDFArticle Synopsis
- Metastatic castration-resistant prostate cancer (mCRPC) is a serious condition with high mortality, and the study aimed to assess the real-world effectiveness and safety of enzalutamide for patients with this disease.
- A total of 158 mCRPC patients were involved, averaging 75.8 years old; results showed that 43.7% had cancer progression during a median follow-up of 7.7 months, with 10.1% experiencing severe side effects.
- The findings support enzalutamide as both effective and safe, with factors like high baseline PSA and previous treatments linked to higher progression rates, while low pain scores and early PSA reductions indicated better outcomes.
Background: Other than the programmed cell death ligand 1 (PD-L1) value, oncologists have only the clinical characteristics of patients with advanced non-small-cell lung cancer (aNSCLC) to determine candidates for immunotherapy. A clinical prognostic score composed of the Eastern Cooperative Oncology Group performance status, sex, histologic type, stage, platinum-based first-line therapy, and response to first-line therapy has categorized 3 prognostic groups for patients undergoing second-line chemotherapy. We sought to validate the same score for patients with aNSCLC treated with second- or further-line immunotherapy.
View Article and Find Full Text PDF